What is Ted W. Love’s Gilead (GILD) share ownership after these awards?

After the reported awards, Ted W. Love directly holds 5,484 shares of Gilead common stock. He also holds a non-qualified stock option covering 4,884 additional shares, all of which are vested and exercisable under the terms disclosed in the Form 4.

Director at Gilead (NASDAQ: GILD) receives new equity awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Gilead Sciences director Ted W. Love received new equity awards as part of his compensation. On April 30, 2026, he was granted 1,146 restricted stock units under the 2022 Equity Incentive Plan. Each RSU represents one share of common stock and vested immediately on the grant date.

On the same date, he was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with all shares under the option vesting immediately and expiring on April 30, 2036. Following these awards, he directly holds 5,484 common shares and 4,884 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LOVE TED W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Option (Right to Buy)	4,884	$0.00	--
Grant/Award	Common Stock	1,146	$0.00	--

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 4,884 shares (Direct, null); Common Stock — 5,484 shares (Direct, null)

Footnotes (1)

Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Key Figures

RSUs granted: 1,146 units Option shares granted: 4,884 shares Option exercise price: $130.84 per share +3 more

6 metrics

RSUs granted 1,146 units Restricted stock units granted April 30, 2026; vested immediately

Option shares granted 4,884 shares Non-qualified stock option granted April 30, 2026

Option exercise price $130.84 per share Exercise price of non-qualified stock option

Option expiration April 30, 2036 Expiration date of non-qualified stock option

Shares held after transaction 5,484 shares Common stock directly owned after April 30, 2026 awards

Options held after transaction 4,884 options Non-qualified stock options directly owned after grant

Key Terms

restricted stock units ("RSUs"), Non-qualified Stock Option (Right to Buy), 2022 Equity Incentive Plan, exercise price

4 terms

restricted stock units ("RSUs") financial

"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-qualified Stock Option (Right to Buy) financial

"Non-qualified Stock Option (Right to Buy) with 4,884 shares at an exercise price of $130.8400."

2022 Equity Incentive Plan financial

"RSUs granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."

exercise price financial

"conversion_or_exercise_price: "130.8400" for the stock option grant."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOVE TED W

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽¹⁾	04/30/2026		A		1,146	A	$0	5,484	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$130.84	04/30/2026		A		4,884		⁽²⁾	04/30/2036	Common Stock	4,884	$0	4,884	D

Explanation of Responses:

1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Remarks:

	/s/ Amy Kim by Power of Attorney for Ted W. Love	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Gilead (GILD) director Ted W. Love acquire in this Form 4?

Ted W. Love received equity awards as compensation, not open-market purchases. He was granted 1,146 restricted stock units and a non-qualified stock option for 4,884 shares, both dated April 30, 2026, under Gilead’s 2022 Equity Incentive Plan.

How many Gilead (GILD) restricted stock units were granted to Ted W. Love?

Ted W. Love was granted 1,146 restricted stock units of Gilead common stock. Each RSU represents the right to receive one share, and all of these RSUs vested immediately on the April 30, 2026 grant date, according to the filing’s footnote disclosure.

What are the terms of Ted W. Love’s new Gilead (GILD) stock options?

He received a non-qualified stock option covering 4,884 Gilead common shares at an exercise price of $130.84 per share. The option fully vested on April 30, 2026 and will expire on April 30, 2036 if not exercised, as described in the filing.

Did the Gilead (GILD) director buy or sell shares in the market?

No open-market buys or sells were reported. The Form 4 shows compensation-related acquisitions coded as “A,” representing grants of RSUs and stock options that vested immediately, rather than discretionary purchases or sales on the public market.

Under which plan were the Gilead (GILD) RSUs granted to Ted W. Love?

The 1,146 RSUs were granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. The footnote explains that each RSU equals one share of common stock and that the entire RSU grant vested immediately on April 30, 2026, the grant date.